Hamburg Glomerulonephritis Registry

The Hamburg Glomerulonephritis Registry will be an integral part of the SFB initiative. Its purpose is to study a large cohort of patients with membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN/C3 glomerulopathy), rapidly progressive glomerulonephritis (ANCA-GN, Lupus Nephritis and anti-GBM-Nephritis), fibrillary glomerulonephritis (FGN) as well as patients with minimal change disease (MCD) and primary focal and segmental glomerulosclerosis (FSGS). Renal biopsies, blood samples as well as genetic and clinical data will be collected from 400 patients with MN, 80 patients with MPGN, 300 patients with RPGN, 20 patients with FGN and 150 patients with MCD/FSGS during the first funding period. Starting point for data collection will be the renal biopsy, followed by regular clinical and laboratory assessments of the participating patients. The clinical assessments will be performed according to the “Hamburg Glomerulonephritis Registry”, which is adapted from the outlines of the Toronto Glomerulonephritis Registry. Participants will be followed longitudinally to enable the PIs of the SFB to better understand the causes of disease, characterise prognostic factors, response to therapy, and disease progression, with the ultimate objective to cure these glomerular diseases.